THEO-24
Details
- Status
- Prescription
- First Approved
- 1983-08-22
- Routes
- ORAL
- Dosage Forms
- CAPSULE, EXTENDED RELEASE
THEO-24 Approval History
What THEO-24 Treats
4 indicationsTHEO-24 is approved for 4 conditions since its original approval in 1983. These indications span multiple therapeutic areas including oncology, immunology, and more.
- Asthma
- Emphysema
- Chronic Bronchitis
- Chronic Lung Disease
Drugs Similar to THEO-24
FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.
Active Pipeline
Ongoing clinical trials by development phase
Key Completed Trials
Completed studies with published results, ranked by significance
Trial Timeline
Full development history with FDA approval milestones
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
THEO-24 FDA Label Details
ProIndications & Usage
Theophylline is indicated for the treatment of the symptoms and reversible airflow obstruction associated with chronic asthma and other chronic lung diseases, e.g., emphysema and chronic bronchitis.
Want competitive intelligence?
See who's developing similar drugs and track their progress
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.